167 related articles for article (PubMed ID: 25049073)
1. Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression.
Ueda M; Hisada H; Temma T; Shimizu Y; Kimura H; Ono M; Nakamoto Y; Togashi K; Saji H
Mol Imaging Biol; 2015 Feb; 17(1):102-10. PubMed ID: 25049073
[TBL] [Abstract][Full Text] [Related]
2. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.
Vosjan MJ; Perk LR; Roovers RC; Visser GW; Stigter-van Walsum M; van Bergen En Henegouwen PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):753-63. PubMed ID: 21210114
[TBL] [Abstract][Full Text] [Related]
3. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
4. PET Imaging of VCAM-1 Expression and Monitoring Therapy Response in Tumor with a
Zhang X; Liu C; Hu F; Zhang Y; Wang J; Gao Y; Jiang Y; Zhang Y; Lan X
Mol Pharm; 2018 Feb; 15(2):609-618. PubMed ID: 29308904
[TBL] [Abstract][Full Text] [Related]
5. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.
Ren G; Zhang R; Liu Z; Webster JM; Miao Z; Gambhir SS; Syud FA; Cheng Z
J Nucl Med; 2009 Sep; 50(9):1492-9. PubMed ID: 19690041
[TBL] [Abstract][Full Text] [Related]
6. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
7. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
8. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H
Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.
Reddy S; Shaller CC; Doss M; Shchaveleva I; Marks JD; Yu JQ; Robinson MK
Clin Cancer Res; 2011 Mar; 17(6):1509-20. PubMed ID: 21177408
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
11. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
12. Selection of the optimal macrocyclic chelators for labeling with
von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
Eur J Pharm Biopharm; 2019 Jul; 140():109-120. PubMed ID: 31082509
[TBL] [Abstract][Full Text] [Related]
13. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
[TBL] [Abstract][Full Text] [Related]
15. [
Toàn NM; Vágner A; Nagy G; Ország G; Nagy T; Csikos C; Váradi B; Sajtos GZ; Kapus I; Szoboszlai Z; Szikra D; Trencsényi G; Tircsó G; Garai I
J Med Chem; 2024 May; 67(10):8261-8270. PubMed ID: 38690886
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the first
Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
[TBL] [Abstract][Full Text] [Related]
17. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
18. Radiochemistry and Preclinical PET Imaging of
Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
[TBL] [Abstract][Full Text] [Related]
19. [
Krajcovicova S; Daniskova A; Bendova K; Novy Z; Soural M; Petrik M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299008
[TBL] [Abstract][Full Text] [Related]
20. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
